Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study

Name: Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study
Start: 2022-11-23T13:30:00+01:00
End: 2022-11-23T14:30:00+01:00
Location: Webinar

This event has passed.

Lysogene will host a live webcast on Wednesday, November 23, 2022 at 1:30 pm CET to provide updates and topline results from the Phase 2/3 AAVance study evaluating LYS-SAF302, an investigational gene therapy for the treatment of MPS IIIA.

Participants may register for the webcast by via the following website https://channel.royalcast.com/lysogene/#!/lysogene/20221123_1

Presentation is available here.

Details

Date:: November 23, 2022
Time:: 1:30 pm - 2:30 pm
Website:: https://channel.royalcast.com/lysogene/#!/lysogene/20221123_1

Venue

Webinar

Organizer

: LYSOGENE

Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study

Details

Venue

Organizer

Lysogene COVID-19 update

Lysogene is developing therapies for children with CNS diseases.

Delivering Gene Therapy’s Promise

©2022 Lysogene. All rights reserved.

Get In Touch